87 / 89
87
69.
Richardson PG, Blood E, Mitsiades CS, Jagannath S,
Zeldenrust SR, Alsina M, et al. A randomized phase 2
study of lenalidomide therapy for patients with relapsed
or relapsed and refractory multiple myeloma. Blood
2006;108:3458-64.
70.
Kropff M, Baylon HG, Hillengass J, Robak T, Hajek R,
Liebisch P, et al. Thalidomide versus dexamethasone for
the treatment of relapsed and/or refractory multiple
myeloma: results from OPTIMUM, a randomized trial.
Haematologica 2012;97:784-91.
71.
Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N,
Holmberg E, Pedersen PT, et al. Thalidomide and
dexamethasone vs. bortezomib and dexamethasone for
melphalan refractory myeloma: a randomized study. Eur
J Haematol 2012;88:485-96.
72.
Chiou TJ, Wang TH, Chao TY, Lin SF, Tang JL, Chen TY,
et al. Randomized Phase II trial of thalidomide alone
versus thalidomide plus interferon alpha in patients with
refractory multiple myeloma. Cancer Invest. 2007;25:140-
7.
73.
Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R,
Spencer A, et al. Randomized phase III study of pegylated
liposomal doxorubicin plus bortezomib compared with
bortezomib alone in relapsed or refractory multiple
myeloma: combination therapy improves time to
progression. J Clin Oncol. 2007;25:3892-901.
74.
Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J,
Robak T, et al. Combined pegylated liposomal
doxorubicin and bortezomib is highly effective in patients
with recurrent or refractory multiple myeloma who
received prior thalidomide/lenalidomide therapy.
Cancer. 2008;112:1529-37.
75.
White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton
VE. Results from AMBER, a randomized phase 2 study of